Managing Director, John Kelly speaks to Proactive about the broad applications for Atomo’s rapid blood-based tests at the ASX Small and Mid-Cap Conference. [embed]https://www.youtube.com/watch?v=wl4xxnxZ198[/embed]...
Atomo Diagnostics (ASX: AT1) has announced that the TGA has approved its rapid SARS-CoV-2 antibody blood test for use by medical professionals in Australia. Read the full article > ...
Managing Director and CEO, John Kelly talks to the ASX about the inspiration behind Atomo, listing on the ASX during COVID-19 and why having the right advisors is crucial when you IPO. Watch the video and read the full interview here > ...
In an article for Stockhead, Morgans senior analyst Scott Power discusses how Atomo’s rapid test for COVID-19 enabled it to list on the ASX in April. Read the full article > ...
Lawyers Weekly discusses Atomo Diagnostics’ $30 million IPO and ASX listing as well its integrated rapid diagnostic test (RDT) devices. Read the full article >...
An article in Bloomberg talks about Atomo’s rapid share price rise after its ASX listing in a broader piece on US IPOs amid COVID-19. Read the full article > ...
An article on the Kalkine Media website discusses Atomo’s ASX listing, its integrated rapid diagnostic test devices and agreement with NG Biotech for the supply of devices for the rapid blood-based testing of antibodies produced in response to COVID 19. Read the full article > ...
An article in WSJ.com looks at Atomo’s strong ASX debut and how its device could produce blood-test results in 15 minutes for COVID-19 testing. Read the full article > ...
CEO John Kelly speaks to David Koch of Ausbiz about the Atomo’s successful ASX listing and support from blue-chip investors. [embed]https://assets.ausbiz.live/assets/e5a23332-74f7-432d-8e99-23fa1907814b/MP4/vimondio_video_1280x720_2000.mp4[/embed]...
SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Australian rapid blood test company Atomo Diagnostics Limited (Atomo) will commence on the Australian Securities Exchange (ASX) today under the ticker code...
Founder and CEO John Kelly speaks to AAP about the company’s ASX debut and the company’s unique position to make a major impact within the COVID-19 environment. The article was syndicated across a range of national, metropolitan and regional press, 7 News.com.au, 9Finance and Yahoo7...
Atomo’s strong perfromance on its first day of being an ASX listed company was featured in markets blogs in the SMH, The Age, Brisbane Times and WA Today. Read the full article > ...
Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Atomo Diagnostics Limited commences on the Australian Securities Exchange (ASX) today under the ticker code AT1. Strong institutional and retail investor demand has led to the company raising...
Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...
$30m Initial Public Offer closes oversubscribed SYDNEY Australia, 01 April 2020: Australian rapid blood test company Atomo Diagnostics Limited (ACN 142 925 684) said today it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s...